Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn. Now this chunk of money will come from amneal's pocket. good luck to everyone with lousy bonuses and pay raise next year and yes continue doing donkey work until this company gets sued more for bad ethics and incorrect FDA procedures.
2 replies (most recent on top)
Sooner or later everyone will realize that this merger was a bad decision for Amneal. Amneal being private had no pressure from SEC and Investors but now with added liabilities it will be negative trend for amneal if things aren’t changed drastically. The biggest strength Amneal has at this point is their foolish workforce which is working like donkey over weekends without paid overtime. This helps Amneal with increased margins and profitability.
Yes this is true, here is the link
https://finance.yahoo.com/news/impax-pay-35-mln-settle-180835370.html